Moderna (NASDAQ:MRNA) and Pharmacyte Biotech (OTCMKTS:PMCB) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Moderna and Pharmacyte Biotech, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Moderna | 0 | 0 | 8 | 0 | 3.00 |
| Pharmacyte Biotech | 0 | 0 | 0 | 0 | N/A |
Moderna presently has a consensus target price of $29.71, indicating a potential upside of 57.30%. Given Moderna’s higher probable upside, research analysts plainly believe Moderna is more favorable than Pharmacyte Biotech.
Institutional and Insider Ownership
50.3% of Moderna shares are owned by institutional investors. Comparatively, 0.0% of Pharmacyte Biotech shares are owned by institutional investors. 34.5% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Moderna and Pharmacyte Biotech’s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Moderna | $135.07 million | 46.61 | -$384.73 million | ($4.95) | -3.82 |
| Pharmacyte Biotech | N/A | N/A | -$4.07 million | N/A | N/A |
Pharmacyte Biotech has lower revenue, but higher earnings than Moderna.
Profitability
This table compares Moderna and Pharmacyte Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Moderna | -652.57% | -38.25% | -30.23% |
| Pharmacyte Biotech | N/A | -80.57% | -71.20% |
Summary
Moderna beats Pharmacyte Biotech on 7 of the 9 factors compared between the two stocks.
About Moderna
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. It has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
About Pharmacyte Biotech
PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the Cannabis plant. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Laguna Hills, California.
Receive News & Ratings for Moderna Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Moderna and related companies with MarketBeat.com’s FREE daily email newsletter.
